Astrotech Reports Fiscal Year 2024 Financial Results
September 19 2024 - 4:30PM
Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”)
reported its financial results for the fiscal year ended June 30,
2024.
Financial Highlights & Fiscal Year
Developments
- Revenue increased to $1.7 million
as Astrotech’s subsidiary, 1st Detect, gained traction in the
international passenger market with its explosives trace detectors
(“ETD”). Gross margin increased to 45% for the year compared to 41%
in the prior period, due to a higher proportion of recurring
revenue.
- The U.S. Transportation Security
Administration (“TSA”) approved the TRACER 1000 for the Air Cargo
Security Technology List, which permits air cargo companies in the
United States to use our equipment in their operations. This action
advances the TRACER 1000 to Stage II testing and allows us to sell
the TRACER 1000 to air cargo companies in the United States. In
Stage II testing, the Company will begin field trials with the
TSA. If field trials are successful, the TRACER 1000 will be added
to the "qualified" list.
- The Company has entered into
Developmental Test and Evaluation in which the Transportation
Security Laboratory ("TSL") will test the TRACER 1000 and work with
1st Detect to ensure its readiness to enter certification testing
for TSA checkpoint testing. The certification test is then
completed by the Independent Test & Evaluation department of
TSL. As of the fiscal year 2023 budget the TSA had over 6,000 ETD
units at checkpoint and baggage screening points which we believe
would benefit from utilizing our AMS Technology.
- 1st Detect began accepting
orders for the TRACER 1000 Narcotics Trace Detector (“NTD”) from
worldwide customers. The TRACER 1000 NTD is a high-performance
laboratory instrument capable of rapid detection of trace levels of
narcotic compounds in seconds. The TRACER 1000 NTD and the TRACER
1000 ETD together provide a comprehensive protection platform that
can be applied across various markets including airports, border
security, checkpoint, cargo, and infrastructure security,
correctional facilities, military, and law enforcement.
- The TRACER 1000 NTD and the TRACER
1000 ETD are now registered with the U.S. General Services
Administration ("GSA") IT Schedule 70 under Contract No.
GS-35F-250GA with SRI Group LLC, Special Item Number 334290.
The IT Schedule 70 is a long-term contract issued by the GSA
to commercial technology vendors that allows sales to the U.S.
federal government, one of the largest buyers of goods and services
in the world. 1st Detect continues to showcase the
TRACER 1000 NTD and TRACER 1000 ETD at trade events in the
U.S.
- We announced the formation of a new
wholly-owned subsidiary, Pro-Control, and Astrotech’s entry into an
exclusive license with Pro-Control to utilize our Astrotech Mass
Spectrometer Technology™ (the “AMS Technology”) for industrial
process control applications involving chemical distillation
outside of the agriculture industry. Pro-Control uses advanced mass
spectrometer instrumentation to monitor and control the production
and operations of manufacturing processes using real-time,
in-process samples.
- AgLAB Inc. (“AgLAB”) and SC
Laboratories (“SC Labs”) entered into a master lease agreement
providing for the joint marketing of the AgLAB 1000-D2™ mass
spectrometer and the AgLAB Maximum Value Process™ (“MVP™”) testing
method to SC Labs’ clients. SC Labs is an industry leader
that provides the regulatory requirement of a Certificate of
Analysis for all movement and sale of all processed cannabis CBD or
THC oils.
- Astrotech presented the AgLAB MVP™
at MJBizcon. The MVP™ is an innovative process control system to
increase the potency of ending-weight yields and revenue by 20% or
more using AgLAB’s proprietary integration of the AMS
Technology.
- Astrotech’s consolidated balance
sheet remains strong with $31.9 million in cash and cash
equivalents and liquid investments which is anticipated to support
the Company’s research and development, organic growth, and
potential acquisition targets.
“Our mission is to expand access to the precision of mass
spectrometry for companies in our target markets. We intend to
achieve our mission through simplification, customization,
automation, and configuration to provide relevant real-time
solutions. Our TRACER 1000 has been TSA approved for air
cargo and is also on the GSA, and we are currently accepting
orders. Both our NTDs and ETDs are being showcased at
tradeshows around the U.S. Our gross profit is growing, and we look
to increasing revenue in subsequent fiscal years,” stated Thomas B.
Pickens, III, Astrotech’s Chairman, Chief Executive Officer and
Chief Technology Officer.
About Astrotech Corporation
Astrotech (Nasdaq: ASTC) is a mass
spectrometry company that launches, manages, and commercializes
scalable companies based on its innovative core technology through
its wholly-owned subsidiaries. 1st
Detect develops, manufactures, and sells trace
detectors for use in the security and detection market.
AgLAB develops and sells chemical analyzers for
use in the agriculture market. Pro-Control is
developing the mass spectrometry technology for use in chemical
manufacturing processes. BreathTech is
developing a breath analysis tool to screen for volatile organic
compounds that could indicate bodily infections and critical
conditions. Astrotech is headquartered in Austin, Texas. For
information, please visit www.astrotechcorp.com.
Forward-Looking Statements
This press release contains forward-looking
statements that are made pursuant to the Safe Harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are subject to risks, trends, and
uncertainties that could cause actual results to be materially
different from the forward-looking statement. These factors
include, but are not limited to, the adverse impact of inflationary
pressures, including significant increases in fuel costs, global
economic conditions and events related to these conditions,
including the ongoing wars in Ukraine and the Middle East and the
COVID-19 pandemic, the Company’s use of proceeds from the common
stock offerings, whether we can successfully complete the
development of our new products and proprietary technologies,
whether we can obtain the FDA and other regulatory approvals
required to market our products under development in the United
States or abroad, whether the market will accept our products and
services and whether we are successful in identifying, completing
and integrating acquisitions, as well as other risk factors and
business considerations described in the Company’s Securities and
Exchange Commission filings including the Company’s most recent
Annual Report on Form 10-K. Any forward-looking statements in this
document should be evaluated in light of these important risk
factors. While we do not intend to directly harvest, manufacture,
distribute or sell cannabis or cannabis products, we may be
detrimentally affected by a change in enforcement by federal or
state governments and we may be subject to additional risks in
connection with the evolving regulatory area and associated
uncertainties. Any such effects may give rise to risks and
uncertainties that are currently unknown or amplify others
mentioned herein. Although the Company believes the expectations
reflected in its forward-looking statements are reasonable and are
based on reasonable assumptions, no assurance can be given that
these assumptions are accurate or that any of these expectations
will be achieved (in full or at all) or will prove to have been
correct. Moreover, such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the
control of the Company, which may cause actual results to differ
materially from those implied or expressed by the forward-looking
statements. In addition, any forward-looking statements included in
this press release represent the Company’s views only as of the
date of its publication and should not be relied upon as
representing its views as of any subsequent date. The Company
assumes no obligation to correct or update these forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by applicable law.
Company
Contact: Jaime Hinojosa, Chief
Financial Officer, Astrotech Corporation, (512) 485-9530.
|
|
Tables follow |
|
|
|
ASTROTECH CORPORATIONConsolidated Statements of
Operations and Comprehensive Loss(In thousands, except per share
data)(Unaudited) |
|
|
|
|
|
June 30, |
|
|
|
2024 |
|
|
2023 |
|
Revenue |
|
$ |
1,664 |
|
|
$ |
750 |
|
Cost of revenue |
|
|
913 |
|
|
|
444 |
|
Gross
profit |
|
|
751 |
|
|
|
306 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
7,241 |
|
|
|
5,775 |
|
Research and development |
|
|
6,790 |
|
|
|
5,591 |
|
Total operating expenses |
|
|
14,031 |
|
|
|
11,366 |
|
Loss from
operations |
|
|
(13,280 |
) |
|
|
(11,060 |
) |
Other income and expense, net |
|
|
1,616 |
|
|
|
1,418 |
|
Loss from operations
before income taxes |
|
|
(11,664 |
) |
|
|
(9,642 |
) |
Income tax expense |
|
|
(2 |
) |
|
|
— |
|
Net loss |
|
$ |
(11,666 |
) |
|
$ |
(9,642 |
) |
Weighted average common shares
outstanding: |
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
1,638 |
|
|
|
1,620 |
|
Basic and diluted net
loss per common share: |
|
|
|
|
|
|
|
|
Net loss per common share |
|
$ |
(7.12 |
) |
|
$ |
(5.95 |
) |
Other comprehensive
loss, net of tax: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(11,666 |
) |
|
$ |
(9,642 |
) |
Available-for-sale securities: |
|
|
|
|
|
|
|
|
Net unrealized gain (loss) |
|
|
276 |
|
|
|
(254 |
) |
Total comprehensive
loss |
|
$ |
(11,390 |
) |
|
$ |
(9,896 |
) |
|
|
ASTROTECH CORPORATIONConsolidated Balance
Sheets(In thousands, except share and per share
data)(Unaudited) |
|
|
|
|
|
June 30, |
|
|
|
2024 |
|
|
2023 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
10,442 |
|
|
$ |
14,208 |
|
Short-term investments |
|
|
21,474 |
|
|
|
27,919 |
|
Accounts receivable |
|
|
77 |
|
|
|
225 |
|
Inventory, net: |
|
|
|
|
|
|
|
|
Raw materials |
|
|
2,038 |
|
|
|
1,379 |
|
Work-in-process |
|
|
66 |
|
|
|
243 |
|
Finished goods |
|
|
370 |
|
|
|
373 |
|
Income tax receivable |
|
|
— |
|
|
|
1 |
|
Prepaid expenses and other current assets |
|
|
261 |
|
|
|
365 |
|
Total current
assets |
|
|
34,728 |
|
|
|
44,713 |
|
Property and equipment, net |
|
|
2,763 |
|
|
|
2,670 |
|
Operating lease right-of-use assets, net |
|
|
119 |
|
|
|
262 |
|
Other assets, net |
|
|
30 |
|
|
|
30 |
|
Total
assets |
|
$ |
37,640 |
|
|
$ |
47,675 |
|
Liabilities and
stockholders’ equity |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
373 |
|
|
$ |
546 |
|
Payroll related accruals |
|
|
1,174 |
|
|
|
633 |
|
Accrued expenses and other liabilities |
|
|
754 |
|
|
|
1,170 |
|
Lease liabilities, current |
|
|
227 |
|
|
|
316 |
|
Total current
liabilities |
|
|
2,528 |
|
|
|
2,665 |
|
Accrued expenses and other liabilities, net of current portion |
|
|
232 |
|
|
|
— |
|
Lease liabilities, net of current portion |
|
|
73 |
|
|
|
291 |
|
Total
liabilities |
|
|
2,833 |
|
|
|
2,956 |
|
Commitments and contingencies
(Note 14) |
|
|
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
Convertible preferred stock, $0.001 par value, 2,500,000 shares
authorized; 280,898 shares of Series D issued and outstanding at
June 30, 2024 and 2023, respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value, 250,000,000 shares authorized at
June 30, 2024 and 2023 respectively; 1,712,045 and 1,692,045 shares
issued at June 30, 2024 and 2023 respectively; 1,701,729 and
1,681,729 outstanding at June 30, 2024 and 2023, respectively |
|
|
190,643 |
|
|
|
190,643 |
|
Treasury shares, 10,316 shares at June 30, 2024 and 2023,
respectively |
|
|
(119 |
) |
|
|
(119 |
) |
Additional paid-in capital |
|
|
82,480 |
|
|
|
81,002 |
|
Accumulated deficit |
|
|
(237,020 |
) |
|
|
(225,354 |
) |
Accumulated other comprehensive loss |
|
|
(1,177 |
) |
|
|
(1,453 |
) |
Total stockholders’
equity |
|
|
34,807 |
|
|
|
44,719 |
|
Total liabilities and
stockholders’ equity |
|
$ |
37,640 |
|
|
$ |
47,675 |
|
Astrotech (NASDAQ:ASTC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Astrotech (NASDAQ:ASTC)
Historical Stock Chart
From Dec 2023 to Dec 2024